28076-1-AP

antibody from Proteintech Group

Targeting: CD274 B7-H, B7-H1, B7H1, PD-L1, PDCD1LG1, PDL1

Provider product page for 28076-1-AP

Western blot

ELISA

Immunocytochemistry

Immunoprecipitation

Immunohistochemistry

Antibody data

Antibody Data
Antigen structure
References [86]
Comments [0]
Validations [0]

Submit

Product number: 28076-1-AP - Provider product page
Provider: Proteintech Group
Product name: PD-L1/CD274 (C-terminal) antibody
Antibody type: Polyclonal
Description: KD/KO validated PD-L1/CD274 (C-terminal) antibody (Cat. #28076-1-AP) is a rabbit polyclonal antibody that shows reactivity with Human, mouse, rat and has been validated for the following applications: IF, IHC, IP, WB, ELISA.
Reactivity: Human, Mouse, Rat
Host: Rabbit
Conjugate: Unconjugated
Isotype: IgG
Vial size: 20ul, 150ul

CD274 protein structure - 28076-1-AP shown in red.

Submitted references Radix Bupleuri-Radix Paeoniae Alba Inhibits the Development of Hepatocellular Carcinoma through Activation of the PTEN/PD-L1 Axis within the Immune Microenvironment.

Zhang F, Zhou K, Yuan W, Sun K
Nutrition and cancer 2024;76(1):63-79

Coactosin-Like Protein 1 (COTL1) Could Be an Immunological and Prognostic Biomarker: From Pan-Cancer Analysis to Low-Grade Glioma Validation.

Wang X, Bai Y, Wang B
Journal of inflammation research 2024;17:1805-1820

Construction of disulfidptosis-based immune response prediction model with artificial intelligence and validation of the pivotal grouping oncogene c-MET in regulating T cell exhaustion.

Li P, Wang S, Wan H, Huang Y, Yin K, Sun K, Jin H, Wang Z
Frontiers in immunology 2024;15:1258475

Vimentin, inversely correlating with infiltration of CD8 + T lymphocytes, promotes nuclear translocation of PD-L1 in esophageal squamous cell carcinoma.

Liang Y, He S, Liu Q, Liu T, Tan Y, Peng T, Huang C, Lu X, Zheng S
Biochimica et biophysica acta. Molecular cell research 2024 Oct;1871(7):119781

lncRNA MIAT promotes luminal B breast cancer cell proliferation, migration, and invasion in vitro.

Mi J, Zhang H, Jiang X, Yi Y, Cao W, Song C, Yuan C
Journal of applied genetics 2024 May;65(2):309-319

Icaritin-curcumol activates CD8(+) T cells through regulation of gut microbiota and the DNMT1/IGFBP2 axis to suppress the development of prostate cancer.

Xu W, Li Y, Liu L, Xie J, Hu Z, Kuang S, Fu X, Li B, Sun T, Zhu C, He Q, Sheng W
Journal of experimental & clinical cancer research : CR 2024 May 23;43(1):149

Aptamer-bivalent-cholesterol-mediated proximity entropy-driven exosomal protein reporter for tumor diagnosis.

Fan Z, Zhou J, Shu Q, Dong Y, Li Y, Zhang T, Bai G, Yu H, Lu F, Li J, Zhao X
Biosensors & bioelectronics 2024 May 1;251:116104

DEAD-box helicase 1 inhibited CD8(+) T cell antitumor activity by inducing PD-L1 expression in hepatocellular carcinoma.

Liu J, Yang T, Luo Y, Ma Z, Yu Z, Zhang L, Liu G, Wen J, Lu G, Zhang G, Zhao Y, Luo W, Li Y, Yang N, Zhou J, Lu Y, Chen S, Zeng X
Cancer science 2024 Mar;115(3):763-776

GSK0660 enhances antitumor immunotherapy by reducing PD-L1 expression.

Khan B, Chen M, Wang H, Khan A, Hussain S, Shi J, Yang L, Hou Y
European journal of pharmacology 2024 Jun 5;972:176565

Nucleoporin 93, a new substrate of the E3 ubiquitin protein ligase HECTD1, promotes esophageal squamous cell carcinoma progression.

Zhang J, Xin Y, Ling X, Liang H, Zhang L, Fang C, Ma J
Human cell 2024 Jan;37(1):245-257

An innovative nanoformulation utilizing tumor microenvironment-responsive PEG-polyglutamic coating and dynamic charge adjustment for specific targeting of ER stress inducer, microRNA, and immunoadjuvant in pancreatic cancer: In vitro investigations.

Li CY, Chou TF, Lo YL
International journal of biological macromolecules 2024 Jan;254(Pt 2):127905

Bioinformatics Analysis Identifies PLA2G7 as a Key Antigen-Presenting Prognostic Related Gene Promoting Hepatocellular Carcinoma through the STAT1/PD-L1 Axis.

Guo S, Yang Q
Frontiers in bioscience (Landmark edition) 2024 Jan 23;29(1):39

The tertiary lymphoid structure-related signature identified PTGDS in regulating PD-L1 and promoting the proliferation and migration of glioblastoma.

Wu W, Li H, Wang Z, Dai Z, Liang X, Luo P, Liu K, Zhang H, Zhang N, Li S, Zhang C
Heliyon 2024 Jan 15;10(1):e23915

MT1G, an emerging ferroptosis-related gene: A novel prognostic biomarker and indicator of immunotherapy sensitivity in prostate cancer.

Cheng B, Lai Y, Huang H, Peng S, Tang C, Chen J, Luo T, Wu J, He H, Wang Q, Huang H
Environmental toxicology 2024 Feb;39(2):927-941

The Identification of Gamma-Glutamyl Hydrolase in Uterine Corpus Endometrial Carcinoma: a Predictive Model and Machine Learning.

Zhu C, Du Y, Huai Q, Fang N, Xu W, Yang J, Li X, Zhang Y, Zhang X, Dai H, Li X, Wang H, Dai Y
Reproductive sciences (Thousand Oaks, Calif.) 2024 Feb;31(2):532-549

A pan-cancer analysis of prognostic significance and immunological role of lysosomal-associated membrane protein 3.

Feng X, Gao L, Shen X, Li M, Wang X, Hao Y, Chen J, Zhai Y, Zou B, Yao S, Guo Y, Zhang L
Journal of cellular and molecular medicine 2024 Feb;28(3):e18088

Proton-Gradient-Driven Porphyrin-Based Liposome Remote-Loaded with Imiquimod as In Situ Nanoadjuvants for Synergistically Augmented Tumor Photoimmunotherapy.

Liu D, Fu L, Gong L, Li S, Li K, Liu K, Yang D
ACS applied materials & interfaces 2024 Feb 21;16(7):8403-8416

Benzosceptrin C induces lysosomal degradation of PD-L1 and promotes antitumor immunity by targeting DHHC3.

Wang Q, Wang J, Yu D, Zhang Q, Hu H, Xu M, Zhang H, Tian S, Zheng G, Lu D, Hu J, Guo M, Cai M, Geng X, Zhang Y, Xia J, Zhang X, Li A, Liu S, Zhang W
Cell reports. Medicine 2024 Feb 20;5(2):101357

Inflammation-Driven Nanohitchhiker Enhances Postoperative Immunotherapy by Alleviating Prostaglandin E2-Mediated Immunosuppression.

Liu Y, He J, Li M, Ren K, Zhao Z
ACS applied materials & interfaces 2024 Feb 14;16(6):6879-6893

TLR9 activation induces immunosuppression and tumorigenesis via PARP1/PD-L1 signaling pathway in oral squamous cell carcinoma.

Ma L, Qin N, Wan W, Song S, Hua S, Jiang C, Li N, Huang L, Gao X
American journal of physiology. Cell physiology 2024 Feb 1;326(2):C362-C381

S100A9 Induces Macrophage M2 Polarization and Immunomodulatory Role in the Lesion Site After Spinal Cord Injury in Rats.

Lv J, Wang Z, Wang B, Deng C, Wang W, Sun L
Molecular neurobiology 2024 Aug;61(8):5525-5540

GHITM regulates malignant phenotype and sensitivity to PD-1 blockade of renal cancer cells via Notch signalling.

Huang S, Liu J, Hu J, Hou Y, Hu M, Zhang B, Luo H, Fu S, Chen Y, Liu X, Chen Z, Wang L
Journal of cellular and molecular medicine 2024 Apr;28(8):e18290

Tackling Esophageal Squamous Cell Carcinoma with ITFn-Pt(IV): A Novel Fusion of PD-L1 Blockade, Chemotherapy, and T-cell Activation.

Xin Q, Wang D, Wang S, Zhang L, Liang Q, Yan X, Fan K, Jiang B
Advanced healthcare materials 2024 Apr;13(11):e2303623

Ginger inhibits the invasion of ovarian cancer cells SKOV3 through CLDN7, CLDN11 and CD274 m6A methylation modifications.

Zhang X, Zhang H, Zhu L, Xia L
BMC complementary medicine and therapies 2024 Apr 4;24(1):145

Scutellarin activates IDH1 to exert antitumor effects in hepatocellular carcinoma progression.

Cui Z, Li C, Liu W, Sun M, Deng S, Cao J, Yang H, Chen P
Cell death & disease 2024 Apr 15;15(4):267

Prognostic biomarker DARS2 correlated with immune infiltrates in bladder tumor.

Yang H, Ma L, Deng W, Fu B, Nie J, Liu X
Frontiers in immunology 2023;14:1301945

Overexpression of DBT suppresses the aggressiveness of renal clear cell carcinoma and correlates with immune infiltration.

Zhang C, Huang G, Yang J, Jiang Y, Huang R, Ye Z, Huang Y, Hu H, Xi X
Frontiers in immunology 2023;14:1197011

Machine learning-based identification of tumor-infiltrating immune cell-associated model with appealing implications in improving prognosis and immunotherapy response in bladder cancer patients.

Chen H, Yang W, Ji Z
Frontiers in immunology 2023;14:1171420

LRPPRC facilitates tumor progression and immune evasion through upregulation of m(6)A modification of PD-L1 mRNA in hepatocellular carcinoma.

Wang H, Tang A, Cui Y, Gong H, Li H
Frontiers in immunology 2023;14:1144774

A prognostic signature based on snoRNA predicts the overall survival of lower-grade glioma patients.

Zhou Y, Yin W, Kuang Y, Wu Z, Huang H, Liu W, Jiang X, Ren C
Frontiers in immunology 2023;14:1138363

Discovery of CDK signature and CDK5 as potential biomarkers for predicting prognosis and immunotherapeutic response in gastric cancer peritoneal metastases.

Sun Y, Chen Y, Cai Y, Wang X, Chen Q, Fang S, Lian M, Lv C, Weng J, Huang R, Zhuang W, Xue F, Cai L, Lin Y, Wang Q
American journal of cancer research 2023;13(9):4087-4100

Epigenetically regulated lncRNAs dissect the intratumoural heterogeneity and facilitate immune evasion of glioblastomas.

Xu D, Cao M, Wang B, Bi X, Zhang H, Wu D, Zhang C, Xu J, Xu Z, Zheng D, Chen L, Li P, Wang H, Liu Y, Jiang H, Li K
Theranostics 2023;13(5):1490-1505

Afatinib combined with anti-PD1 enhances immunotherapy of hepatocellular carcinoma via ERBB2/STAT3/PD-L1 signaling.

Yu C, Zhang X, Wang M, Xu G, Zhao S, Feng Y, Pan C, Yang W, Zhou J, Shang L, Ma Y
Frontiers in oncology 2023;13:1198118

FAT4 overexpression promotes antitumor immunity by regulating the β-catenin/STT3/PD-L1 axis in cervical cancer.

Wang D, Wu S, He J, Sun L, Zhu H, Zhang Y, Liu S, Duan X, Wang Y, Xu T
Journal of experimental & clinical cancer research : CR 2023 Sep 1;42(1):222

Anoikis resistance and immune escape mediated by Epstein-Barr virus-encoded latent membrane protein 1-induced stabilization of PGC-1α promotes invasion and metastasis of nasopharyngeal carcinoma.

Liao C, Li M, Chen X, Tang C, Quan J, Bode AM, Cao Y, Luo X
Journal of experimental & clinical cancer research : CR 2023 Oct 7;42(1):261

Construction and Evaluation of Novel Dual-function Antifungal Inhibitors and Covalent Organic Framework Carriers Based on the Infection Microenvironment.

Liu Y, Wang Q, Yu S, Liu M, Han J, Sun B
Journal of medicinal chemistry 2023 Oct 12;66(19):13838-13857

Engineering high-affinity dual targeting cellular nanovesicles for optimised cancer immunotherapy.

Zhang L, Zhao X, Niu Y, Ma X, Yuan W, Ma J
Journal of extracellular vesicles 2023 Nov;12(11):e12379

Electroacupuncture Alleviates CFA-Induced Inflammatory Pain via PD-L1/PD-1-SHP-1 Pathway.

Deng D, Xu F, Ma L, Zhang T, Wang Y, Huang S, Zhao W, Chen X
Molecular neurobiology 2023 May;60(5):2922-2936

SHFM1 deficiency suppresses esophageal squamous cell carcinomas progression via modulating NF‑κB signaling and enhancing nature killer cell‑mediated tumor surveillance.

Wu Y, Wang Z, Li S, Chen X, Zhou S
Experimental and therapeutic medicine 2023 May;25(5):195

Chang Wei Qing Decoction enhances the anti-tumor effect of PD-1 inhibitor therapy by regulating the immune microenvironment and gut microbiota in colorectal cancer.

Wang T, Wu L, Wang S, Shi X, Liu H, Deng W
Chinese journal of natural medicines 2023 May;21(5):333-345

PD-L1 Exon 3 Is a Hidden Switch of Its Expression and Function in Oral Cancer Cells.

Yan L, Sun Y, Guo J, Jia R
International journal of molecular sciences 2023 May 3;24(9)

Prognostic and immunotherapeutic predictive value of interleukin enhancer-binding factor 3 in hepatocellular carcinoma: Integrated bioinformatics and experimental analysis.

Qiu J, Wu X, Luo Y, Yao Y, Zhang X, Pan B, Wang X, Tang N
Gene 2023 Mar 10;856:147132

ZNF480 influences the prognosis, pathogenesis, and immune microenvironment in patients with lower-grade glioma.

Zhu Q, Liu Z, Cheng X, Liang W, Wang H, Li P, Zhang J, Chen Y, Gao Y, Qian R
Heliyon 2023 Jul;9(7):e18185

Increased OIT3 in macrophages promotes PD-L1 expression and hepatocellular carcinogenesis via NF-κB signaling.

Wen J, Yang S, Yan G, Lei J, Liu X, Zhang N, Zhang J, Deng H, Wu L, Li Y
Experimental cell research 2023 Jul 15;428(2):113651

mTOR inhibitor, gemcitabine and PD-L1 antibody blockade combination therapy suppresses pancreatic cancer progression via metabolic reprogramming and immune microenvironment remodeling in Trp53(flox/+)LSL-Kras(G12D/+)Pdx-1-Cre murine models.

Qiu J, Feng M, Yang G, Cao Z, Liu Y, You L, Zhang T
Cancer letters 2023 Feb 1;554:216020

Inhibition of ACLY overcomes cancer immunotherapy resistance via polyunsaturated fatty acids peroxidation and cGAS-STING activation.

Xiang W, Lv H, Xing F, Sun X, Ma Y, Wu L, Lv G, Zong Q, Wang L, Wu Z, Feng Q, Yang W, Wang H
Science advances 2023 Dec 8;9(49):eadi2465

E3 ligase Trim35 inhibits LSD1 demethylase activity through K63-linked ubiquitination and enhances anti-tumor immunity in NSCLC.

Tang F, Lu C, He X, Lin W, Xie B, Gao X, Peng Y, Yang D, Sun L, Weng L
Cell reports 2023 Dec 26;42(12):113477

Relationship between the expression of PD-L1 and (18)F-FDG uptake in pancreatic ductal adenocarcinoma.

Li J, Chen R, Chen Y, Xia Q, Zhou X, Xia Q, Wang C, Wan L, Bao H, Huang G, Liu J
British journal of cancer 2023 Aug;129(3):541-550

m(6)A reader YTHDF3 is associated with clinical prognosis, related RNA signatures and immunosuppression in gastric cancer.

Yu Y, Meng LL, Chen XY, Fan HN, Chen M, Zhang J, Zhu JS
Cellular signalling 2023 Aug;108:110699

Biosynthesized gold nanoparticles that activate Toll-like receptors and elicit localized light-converting hyperthermia for pleiotropic tumor immunoregulation.

Qin H, Chen Y, Wang Z, Li N, Sun Q, Lin Y, Qiu W, Qin Y, Chen L, Chen H, Li Y, Shi J, Nie G, Zhao R
Nature communications 2023 Aug 24;14(1):5178

Sensitive and quantitative in vivo analysis of PD-L1 using magnetic particle imaging and imaging-guided immunotherapy.

Peng Z, Lu C, Shi G, Yin L, Liang X, Song G, Tian J, Du Y
European journal of nuclear medicine and molecular imaging 2023 Apr;50(5):1291-1305

The role of YAP1 in survival prediction, immune modulation, and drug response: A pan-cancer perspective.

Hu X, Zhang Y, Yu H, Zhao Y, Sun X, Li Q, Wang Y
Frontiers in immunology 2022;13:1012173

Bacteria-mediated metformin-loaded peptide hydrogel reprograms the tumor immune microenvironment in glioblastoma.

Zhu L, Liu J, Qiu M, Chen J, Liang Q, Peng G, Zou Z
Biomaterials 2022 Sep;288:121711

Multimodal Imaging Response after the Singular or Combination Treatments of Vascular Endothelial Growth Factor Inhibitor and Immune Checkpoint Inhibitor.

Ren Y, Pan F, Kan X, Wang J, Han P, Yan J, Li L, Sun P, Liu CY, Bao Q, Yang L, Zheng C
Molecular pharmaceutics 2022 Oct 3;19(10):3664-3672

Gasdermin D restricts anti-tumor immunity during PD-L1 checkpoint blockade.

Jiang Y, Yang Y, Hu Y, Yang R, Huang J, Liu Y, Wu Y, Li S, Ma C, Humphries F, Wang B, Wang X, Hu Z, Yang S
Cell reports 2022 Oct 25;41(4):111553

BMSCs improve TNBS-induced colitis in rats by inducing Treg differentiation by expressing PD-L1.

Gao F, Cui D, Zuo D, Shou Z, Yang J, Yu T, Liu Y, Chu S, Zhu F, Wei C
Biotechnology letters 2022 Nov;44(11):1263-1275

MicroRNA-20a promotes non-small cell lung cancer proliferation by upregulating PD-L1 by targeting PTEN.

Gong J, Shen Y, Jiang F, Wang Y, Chu L, Sun J, Shen P, Chen M
Oncology letters 2022 May;23(5):148

Immunotherapy landscape analyses of necroptosis characteristics for breast cancer patients.

Yu H, Lv W, Tan Y, He X, Wu Y, Wu M, Zhang Q
Journal of translational medicine 2022 Jul 21;20(1):328

A novel FBW7/NFAT1 axis regulates cancer immunity in sunitinib-resistant renal cancer by inducing PD-L1 expression.

Liu W, Ren D, Xiong W, Jin X, Zhu L
Journal of experimental & clinical cancer research : CR 2022 Jan 26;41(1):38

Comprehensive analysis of N(6)-methyladenosine regulators with the tumor immune landscape and correlation between the insulin-like growth factor 2 mRNA-binding protein 3 and programmed death ligand 1 in bladder cancer.

Cui J, Zhu Y, Liu X, Wang W, Jiang X, Xia Y, Zhou G, Chen S, Shi B
Cancer cell international 2022 Feb 11;22(1):72

Allosteric Regulation of IGF2BP1 as a Novel Strategy for the Activation of Tumor Immune Microenvironment.

Liu Y, Guo Q, Yang H, Zhang XW, Feng N, Wang JK, Liu TT, Zeng KW, Tu PF
ACS central science 2022 Aug 24;8(8):1102-1115

Cancer-cell-biomimetic nanoparticles systemically eliminate hypoxia tumors by synergistic chemotherapy and checkpoint blockade immunotherapy.

Yao Y, Chen H, Tan N
Acta pharmaceutica Sinica. B 2022 Apr;12(4):2103-2119

Berry anthocyanidins inhibit intestinal polyps and colon tumors by modulation of Src, EGFR and the colon inflammatory environment.

Mudd AM, Gu T, Munagala R, Jeyabalan J, Fraig M, Egilmez NK, Gupta RC
Oncoscience 2021;8:120-133

IFNγ/PD-L1 Signaling Improves the Responsiveness of Anti-PD-1 Therapy in Colorectal Cancer: An in vitro Study.

Yuan W, Deng D, Li H, Hu X, Shang X, Hou X, Jiang H, He H
OncoTargets and therapy 2021;14:3051-3062

c-Myb facilitates immune escape of esophageal adenocarcinoma cells through the miR-145-5p/SPOP/PD-L1 axis.

Zhang L, Wang X, Li Y, Han J, Gao X, Li S, Wang F
Clinical and translational medicine 2021 Sep;11(9):e464

What Do We Have to Know about PD-L1 Expression in Prostate Cancer? A Systematic Literature Review. Part 1: Focus on Immunohistochemical Results with Discussion of Pre-Analytical and Interpretation Variables.

Palicelli A, Bonacini M, Croci S, Magi-Galluzzi C, Cañete-Portillo S, Chaux A, Bisagni A, Zanetti E, De Biase D, Melli B, Sanguedolce F, Ragazzi M, Bonasoni MP, Soriano A, Ascani S, Zizzo M, Castro Ruiz C, De Leo A, Giordano G, Landriscina M, Carrieri G, Cormio L, Berney DM, Athanazio D, Gandhi J, Cavazza A, Santandrea G, Tafuni A, Zanelli M
Cells 2021 Nov 14;10(11)

Doxorubicin and PD-L1 siRNA co-delivery with stem cell membrane-coated polydopamine nanoparticles for the targeted chemoimmunotherapy of PCa bone metastases.

Mu X, Zhang M, Wei A, Yin F, Wang Y, Hu K, Jiang J
Nanoscale 2021 May 21;13(19):8998-9008

A hybrid membrane coating nanodrug system against gastric cancer via the VEGFR2/STAT3 signaling pathway.

Long Y, Wang Z, Fan J, Yuan L, Tong C, Zhao Y, Liu B
Journal of materials chemistry. B 2021 May 12;9(18):3838-3855

Promoting the activation of T cells with glycopolymer-modified dendritic cells by enhancing cell interactions.

Yu L, Feng R, Zhu L, Hao Q, Chu J, Gu Y, Luo Y, Zhang Z, Chen G, Chen H
Science advances 2020 Nov;6(47)

Identification and validation of a combined hypoxia and immune index for triple-negative breast cancer.

Zheng S, Zou Y, Liang JY, Xiao W, Yang A, Meng T, Lu S, Luo Z, Xie X
Molecular oncology 2020 Nov;14(11):2814-2833

Tumor-associated macrophages induce PD-L1 expression in gastric cancer cells through IL-6 and TNF-ɑ signaling.

Ju X, Zhang H, Zhou Z, Chen M, Wang Q
Experimental cell research 2020 Nov 15;396(2):112315

New insight on the correlation of metabolic status on (18)F-FDG PET/CT with immune marker expression in patients with non-small cell lung cancer.

Wang Y, Zhao N, Wu Z, Pan N, Shen X, Liu T, Wei F, You J, Xu W, Ren X
European journal of nuclear medicine and molecular imaging 2020 May;47(5):1127-1136

Anti-PD-1 antibody combined with chemotherapy suppresses the growth of mesothelioma by reducing myeloid-derived suppressor cells.

Otsuka K, Mitsuhashi A, Goto H, Hanibuchi M, Koyama K, Ogawa H, Ogino H, Saijo A, Kozai H, Yoneda H, Tobiume M, Kishuku M, Ishizawa K, Nishioka Y
Lung cancer (Amsterdam, Netherlands) 2020 Aug;146:86-96

An update of knowledge on PD-L1 in head and neck cancers: Physiologic, prognostic and therapeutic perspectives.

Lenouvel D, González-Moles MÁ, Talbaoui A, Ramos-García P, González-Ruiz L, Ruiz-Ávila I, Gil-Montoya JA
Oral diseases 2020 Apr;26(3):511-526

Changes in Tumor-Infiltrating Lymphocytes and Vascular Normalization in Breast Cancer Patients After Neoadjuvant Chemotherapy and Their Correlations With DFS.

Wang Q, Xiang Q, Yu L, Hu T, Chen Y, Wang J, Nie X, Cheng J
Frontiers in oncology 2019;9:1545

Verteporfin suppresses the proliferation, epithelial-mesenchymal transition and stemness of head and neck squamous carcinoma cells via inhibiting YAP1.

Liu K, Du S, Gao P, Zheng J
Journal of Cancer 2019;10(18):4196-4207

All-trans retinoic acid induces anti-tumor effects via STAT3 signaling inhibition in oral squamous cell carcinoma and oral dysplasia.

Chen XJ, He MJ, Zhou G
Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology 2019 Oct;48(9):832-839

Retinoic Acid-Related Orphan Receptor C Regulates Proliferation, Glycolysis, and Chemoresistance via the PD-L1/ITGB6/STAT3 Signaling Axis in Bladder Cancer.

Cao D, Qi Z, Pang Y, Li H, Xie H, Wu J, Huang Y, Zhu Y, Shen Y, Zhu Y, Dai B, Hu X, Ye D, Wang Z
Cancer research 2019 May 15;79(10):2604-2618

PD-1 Blockade Following Isolated Limb Perfusion with Vaccinia Virus Prevents Local and Distant Relapse of Soft-tissue Sarcoma.

Smith HG, Mansfield D, Roulstone V, Kyula-Currie JN, McLaughlin M, Patel RR, Bergerhoff KF, Paget JT, Dillon MT, Khan A, Melcher A, Thway K, Harrington KJ, Hayes AJ
Clinical cancer research : an official journal of the American Association for Cancer Research 2019 Jun 1;25(11):3443-3454

DCUN1D1 facilitates tumor metastasis by activating FAK signaling and up-regulates PD-L1 in non-small-cell lung cancer.

Li J, Yu T, Yan M, Zhang X, Liao L, Zhu M, Lin H, Pan H, Yao M
Experimental cell research 2019 Jan 15;374(2):304-314

Hyperresponsiveness to interferon gamma exposure as a response mechanism to anti-PD-1 therapy in microsatellite instability colorectal cancer.

Yuan W, Deng D, Jiang H, Tu C, Shang X, He H, Niu R, Dong J
Cancer immunology, immunotherapy : CII 2019 Feb;68(2):257-268

PD-L1 regulates tumorigenesis and autophagy of ovarian cancer by activating mTORC signaling.

Gao H, Zhang J, Ren X
Bioscience reports 2019 Dec 20;39(12)

The prognostic role of PD-L1 expression for survival in head and neck squamous cell carcinoma: A systematic review and meta-analysis.

Yang WF, Wong MCM, Thomson PJ, Li KY, Su YX
Oral oncology 2018 Nov;86:81-90

Programmed death-ligand 1 (PD-L1) expression in pleomorphic carcinoma of the lung.

Imanishi N, Hirai A, Yoneda K, Shimajiri S, Kuwata T, Tashima Y, Takeuchi M, Iwai Y, Ichiki Y, Tanaka F
Journal of surgical oncology 2018 Jun;117(7):1563-1569

The expression of PD-L1 protein as a prognostic factor in lung squamous cell carcinoma.

Takada K, Okamoto T, Toyokawa G, Kozuma Y, Matsubara T, Haratake N, Akamine T, Takamori S, Katsura M, Shoji F, Oda Y, Maehara Y
Lung cancer (Amsterdam, Netherlands) 2017 Feb;104:7-15

Associations among pretreatment tumor necrosis and the expression of HIF-1α and PD-L1 in advanced oral squamous cell carcinoma and the prognostic impact thereof.

Chen TC, Wu CT, Wang CP, Hsu WL, Yang TL, Lou PJ, Ko JY, Chang YL
Oral oncology 2015 Nov;51(11):1004-1010

No comments: Submit comment

No validations: Submit validation data